Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
EBITDA Growth
136.30%
Quarterly · Period ending:
LCTX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported136.30%period ending
Latest reported136.30%period ending
LCTX Quarterly EBITDA YoY % (-100.00% → 136.30%)
Year-over-year change
High-resolution chart · PNG
LCTX ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 18.042% | |
| 31.0462% | |
| 30.0542% | |
| 47.2358% | |
| -22.9949% | |
| -70.1765% | |
| -100% | |
| -57.1429% | |
| 33.3333% | |
| -9.0909% | |
| 41.6667% | |
| -140% | |
| -28.5714% | |
| -83.3333% | |
| 42.8571% | |
| -600% | |
| -800% | |
| -50% | |
| -162.5% | |
| 120% | |
| 116.6667% | |
| 0% | |
| -33.3333% | |
| -150% | |
| -100% | |
| -33.3333% | |
| -50% | |
| 0% | |
| 0% | |
| -50% | |
| 0% | |
| -100% |